{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:53:14Z","timestamp":1793033594812,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["HG011792"],"award-info":[{"award-number":["HG011792"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA221870"],"award-info":[{"award-number":["R01 CA221870"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008069","name":"University of California, San Francisco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jval.2023.08.010","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T23:25:45Z","timestamp":1695338745000},"page":"1697-1710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non\u2013Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis"],"prefix":"10.1016","volume":"26","author":[{"given":"Jeroen P.","family":"Jansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera V.","family":"Ragavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jval.2023.08.010_bib3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-021-01121-2","article-title":"Targeted therapy in advanced non-small cell lung cancer: current advances and future trends","volume":"14","author":"Majeed","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"2","key":"10.1016\/j.jval.2023.08.010_bib4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/0284186X.2017.1404634","article-title":"A\u00a0systematic review of targeted agents for non-small cell lung cancer","volume":"57","author":"Vestergaard","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jval.2023.08.010_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-019-0099-9","article-title":"The emerging treatment landscape of targeted therapy in non-small-cell lung cancer","volume":"4","author":"Yuan","year":"2019","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.jval.2023.08.010_bib6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non\u2013small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.jval.2023.08.010_bib7","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"5","key":"10.1016\/j.jval.2023.08.010_bib8","article-title":"Metastatic NSCLCs with limited tissues: how to effectively identify driver alterations to guide targeted therapy in Chinese patients","volume":"2","author":"Li","year":"2021","journal-title":"JTO Clin Res Rep"},{"issue":"4","key":"10.1016\/j.jval.2023.08.010_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196556","article-title":"Performance of next-generation sequencing on small tumor specimens and\/or low tumor content samples using a commercially available platform","volume":"13","author":"Morris","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jval.2023.08.010_bib10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.29089","article-title":"Clinical next-generation sequencing in patients with non-small cell lung cancer","volume":"121","author":"Hagemann","year":"2015","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jval.2023.08.010_bib11","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","article-title":"Liquid biopsy for advanced non-small cell lung cancer (NSCLC): A statement paper from the IASLC","volume":"13","author":"Rolfo","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jval.2023.08.010_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13073-022-01041-x","article-title":"Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology","volume":"14","author":"Adib","year":"2022","journal-title":"Genome Med"},{"issue":"15","key":"10.1016\/j.jval.2023.08.010_bib13","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non\u2013small cell lung cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jval.2023.08.010_bib14","article-title":"Prospective clinical validation of the InVisionFirst-lung circulating tumor DNA assay for molecular profiling of patients with advanced nonsquamous non\u2013small-cell lung cancer","volume":"3","author":"Pritchett","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.jval.2023.08.010_bib15","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jtho.2017.07.014","article-title":"Concordance between comprehensive cancer genome profiling in plasma and tumor specimens","volume":"12","author":"M\u00fcller","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"issue":"2","key":"10.1016\/j.jval.2023.08.010_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41416-020-01038-6","article-title":"Cancer health disparities in racial\/ethnic minorities in the United States","volume":"124","author":"Zavala","year":"2021","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.jval.2023.08.010_bib17","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00432-022-04034-w","article-title":"Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach","volume":"149","author":"Englmeier","year":"2023","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"5","key":"10.1016\/j.jval.2023.08.010_bib18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40273-022-01131-z","article-title":"Assessments of the value of new interventions should include health equity impact","volume":"40","author":"Jansen","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2023.08.010_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13584-017-0162-3","article-title":"Equity in HTA: what doesn\u2019t get measured, gets marginalised","volume":"6","author":"Cookson","year":"2017","journal-title":"Isr J Health Policy Res"},{"issue":"1","key":"10.1016\/j.jval.2023.08.010_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/0272989X15583266","article-title":"Distributional cost-effectiveness analysis: a tutorial","volume":"36","author":"Asaria","year":"2016","journal-title":"Med Decis Making"},{"issue":"6","key":"10.1016\/j.jval.2023.08.010_bib21","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/hec.3058","article-title":"Distributional cost-effectiveness analysis of health care programmes--a methodological case study of the UK Bowel Cancer Screening Programme","volume":"24","author":"Asaria","year":"2015","journal-title":"Health Econ"},{"issue":"Pt 2","key":"10.1016\/j.jval.2023.08.010_bib22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1017\/S1744133109004903","article-title":"Explicit incorporation of equity considerations into economic evaluation of public health interventions","volume":"4","author":"Cookson","year":"2009","journal-title":"Health Econ Policy Law"},{"issue":"2","key":"10.1016\/j.jval.2023.08.010_bib23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jval.2016.11.027","article-title":"Using cost-effectiveness analysis to address health equity concerns","volume":"20","author":"Cookson","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2023.08.010_bib24","series-title":"Distributional Cost-Effectiveness Analysis: Quantifying Health Equity Impacts and Trade-Offs","year":"2020"},{"key":"10.1016\/j.jval.2023.08.010_bib26","doi-asserted-by":"crossref","DOI":"10.3402\/gha.v8.27106","article-title":"Inequalities in health: definitions, concepts, and theories","volume":"8","author":"Arcaya","year":"2015","journal-title":"Glob Health Action"},{"issue":"10","key":"10.1016\/j.jval.2023.08.010_bib27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2023.08.010_bib28","series-title":"Distributional Cost-Effectiveness Analysis: Quantifying Health Equity Impacts and Trade-Offs","first-page":"174","article-title":"Love-Koh J. Health opportunity costs","year":"2020"},{"issue":"3","key":"10.1016\/j.jval.2023.08.010_bib29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0022-0531(70)90039-6","article-title":"On the measurement of inequality","volume":"2","author":"Atkinson","year":"1970","journal-title":"J\u00a0Econ Theor"},{"issue":"3","key":"10.1016\/j.jval.2023.08.010_bib30","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/0022-0531(76)90037-5","article-title":"Unequal inequalities.I","volume":"12","author":"Kolm","year":"1976","journal-title":"J\u00a0Econ Theor"},{"issue":"5","key":"10.1016\/j.jval.2023.08.010_bib31","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jval.2019.03.006","article-title":"Aggregate distributional cost-effectiveness analysis of health technologies","volume":"22","author":"Love-Koh","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2023.08.010_bib33","author":"Hill"},{"issue":"2","key":"10.1016\/j.jval.2023.08.010_bib34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jval.2022.08.010","article-title":"The impact of funding inpatient treatments for COVID-19 on health equity in the United States: a distributional cost-effectiveness analysis","volume":"26","author":"Kowal","year":"2023","journal-title":"Value Health"},{"issue":"suppl 2","key":"10.1016\/j.jval.2023.08.010_bib36","doi-asserted-by":"crossref","first-page":"ii32","DOI":"10.1093\/annonc\/mdz067.002","article-title":"Prevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC)","volume":"30","author":"Planchard","year":"2019","journal-title":"Ann Oncol"},{"issue":"56","key":"10.1016\/j.jval.2023.08.010_bib37","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.18632\/oncotarget.27212","article-title":"Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center","volume":"10","author":"Choudhury","year":"2019","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.jval.2023.08.010_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2019.09.169","article-title":"P2.06 lung cancer driver mutations and PD-L1 expression in US latino patients with advanced lung cancer","volume":"14","author":"Saravia","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jval.2023.08.010_bib39","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41379-019-0327-4","article-title":"\u201cInterchangeability\u201d of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy","volume":"33","author":"Torlakovic","year":"2020","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.jval.2023.08.010_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209709","article-title":"Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA","volume":"14","author":"Li","year":"2019","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jval.2023.08.010_bib41","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1634\/theoncologist.2020-0011","article-title":"Real-world treatment patterns and progression-free survival associated with Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitor therapies for ALK+ non-small cell lung cancer","volume":"25","author":"Jahanzeb","year":"2020","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.jval.2023.08.010_bib42","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaoncol.2021.0546","article-title":"Association between KRAS variant status and outcomes with first-line immune checkpoint inhibitor-based therapy in patients with advanced non-small-cell lung cancer","volume":"7","author":"Sun","year":"2021","journal-title":"JAMA Oncol"},{"issue":"17","key":"10.1016\/j.jval.2023.08.010_bib43","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2217\/cer-2021-0131","article-title":"Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC [published correction appears in J Comp Eff Res. 2022;11(7):545-548]","volume":"10","author":"Doebele","year":"2021","journal-title":"J\u00a0Comp Eff Res"},{"issue":"5","key":"10.1016\/j.jval.2023.08.010_bib44","article-title":"Clinical outcomes with dabrafenib plus trametinib in a clinical trial versus Real-World standard of care in patients with BRAF-mutated advanced NSCLC","volume":"3","author":"Johnson","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jval.2023.08.010_bib45","article-title":"Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive lung cancers","volume":"6","author":"Drilon","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"10.1016\/j.jval.2023.08.010_bib46","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1007\/s12325-022-02163-9","article-title":"Matching-Adjusted Indirect Comparison (MAIC) of tepotinib with other MET inhibitors for the treatment of advanced NSCLC with MET Exon 14 skipping mutations","volume":"39","author":"Paik","year":"2022","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.jval.2023.08.010_bib47","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1038\/s41467-022-30908-1","article-title":"Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer","volume":"13","author":"Popat","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jval.2023.08.010_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.834761","article-title":"Long-term real-world outcomes of first-line pembrolizumab monotherapy for metastatic non-small cell lung cancer with \u226550% expression of programmed cell death-ligand 1","volume":"12","author":"Velcheti","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jval.2023.08.010_bib49","doi-asserted-by":"crossref","first-page":"9222","DOI":"10.1038\/s41598-021-88453-8","article-title":"Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices","volume":"11","author":"Velcheti","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jval.2023.08.010_bib50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jval.2023.08.010_bib51","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/ajco.13234","article-title":"Impact of Asian ethnicity on outcome in metastatic EGFR-mutant non-small cell lung cancer","volume":"15","author":"Gibson","year":"2019","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.jval.2023.08.010_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.971033","article-title":"Systematic pan-cancer analysis showed that RAD51AP1 was associated with immune microenvironment, tumor stemness, and prognosis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.jval.2023.08.010_bib54","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cam4.4427","article-title":"Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung cancer outcomes in the real world","volume":"11","author":"Shokoohi","year":"2022","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.jval.2023.08.010_bib55","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cllc.2022.11.007","article-title":"Liquid biopsy versus tissue biopsy to determine front line therapy in metastatic non-small cell lung cancer (NSCLC)","volume":"24","author":"Raez","year":"2023","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"10.1016\/j.jval.2023.08.010_bib56","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/JTO.0b013e318299243b","article-title":"Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting","volume":"8","author":"Chouaid","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jval.2023.08.010_bib57","first-page":"457","article-title":"Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer","volume":"25","author":"Vanderpoel","year":"2022","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.jval.2023.08.010_bib58","first-page":"816","article-title":"Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States","volume":"24","author":"Stargardter","year":"2021","journal-title":"J\u00a0Med Econ"},{"issue":"12","key":"10.1016\/j.jval.2023.08.010_bib59","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.jval.2023.08.010_bib60","article-title":"Real-world treatment patterns and outcomes among patients with metastatic NSCLC previously treated with programmed cell death Protein-1\/Programmed death-ligand 1 inhibitors","volume":"3","author":"Bains","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"15","key":"10.1016\/j.jval.2023.08.010_bib61","doi-asserted-by":"crossref","first-page":"e21620","DOI":"10.1200\/JCO.2020.38.15_suppl.e21620","article-title":"Real-world outcomes after second-line treatment in non-small cell lung cancer (NSCLC) patients treated with immunotherapy","volume":"38","author":"Marmarelis","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2023.08.010_bib62","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.jval.2023.08.010_bib63","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1038\/s41598-021-85696-3","article-title":"Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands","volume":"11","author":"Cramer-van der Welle","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jval.2023.08.010_bib64","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/0284186X.2019.1711165","article-title":"Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study","volume":"59","author":"Tendler","year":"2020","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.jval.2023.08.010_bib69","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/M20-1392","article-title":"A\u00a0health opportunity cost threshold for cost-effectiveness analysis in the United States","volume":"174","author":"Vanness","year":"2021","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.jval.2023.08.010_bib70","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/aje\/kwi307","article-title":"Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods","volume":"162","author":"Zhou","year":"2005","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.jval.2023.08.010_bib71","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s12094-022-02796-w","article-title":"Clinical impact of delays in the management of lung cancer patients in the last decade: systematic review","volume":"24","author":"Guirado","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jval.2023.08.010_bib72","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2020.03.005","article-title":"Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer","volume":"143","author":"Sheinson","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jval.2023.08.010_bib73","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2020.07.033","article-title":"Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling","volume":"148","author":"Madison","year":"2020","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.jval.2023.08.010_bib74","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40273-021-01075-w","article-title":"Why the gap in evaluating the social constructs and the value of medicines?","volume":"39","author":"McRae","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"10.1016\/j.jval.2023.08.010_bib75","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1164\/rccm.202008-3053ST","article-title":"Addressing disparities in lung cancer screening eligibility and healthcare access. An official American Thoracic Society statement","volume":"202","author":"Rivera","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jval.2023.08.010_bib76","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2021.7083","article-title":"Associations between Medicaid insurance, biomarker testing, and outcomes in patients with advanced NSCLC","volume":"20","author":"Gross","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jval.2023.08.010_bib77","article-title":"Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States","volume":"6","author":"Bruno","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jval.2023.08.010_bib78","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lungcan.2022.03.004","article-title":"Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in the US Oncology Network","volume":"166","author":"Robert","year":"2022","journal-title":"Lung Cancer"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523031261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523031261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:33:16Z","timestamp":1761096796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301523031261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1098301523031261"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2023.08.010","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non\u2013Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2023.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}